Masimo Co. (NASDAQ:MASI) Shares Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB increased its position in shares of Masimo Co. (NASDAQ:MASI) by 6.8% during the 4th quarter, HoldingsChannel reports. The fund owned 9,430 shares of the medical equipment provider’s stock after acquiring an additional 600 shares during the quarter. Handelsbanken Fonder AB’s holdings in Masimo were worth $1,105,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. Massmutual Trust Co. FSB ADV grew its stake in shares of Masimo by 140.6% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares during the period. Byrne Asset Management LLC acquired a new position in Masimo in the fourth quarter valued at approximately $28,000. NBC Securities Inc. purchased a new position in Masimo in the third quarter worth approximately $34,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Masimo during the fourth quarter worth $36,000. Finally, Fifth Third Bancorp raised its position in Masimo by 145.8% in the fourth quarter. Fifth Third Bancorp now owns 590 shares of the medical equipment provider’s stock valued at $69,000 after purchasing an additional 350 shares during the period. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on MASI shares. Wells Fargo & Company upgraded Masimo from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $117.00 to $160.00 in a report on Monday, March 25th. Piper Sandler increased their target price on shares of Masimo from $70.00 to $117.00 and gave the stock a “neutral” rating in a research note on Monday, February 26th. StockNews.com raised shares of Masimo from a “sell” rating to a “hold” rating in a research note on Friday, March 29th. BTIG Research increased their price objective on shares of Masimo from $145.00 to $166.00 and gave the stock a “buy” rating in a research report on Monday, March 25th. Finally, Stifel Nicolaus raised Masimo from a “hold” rating to a “buy” rating and boosted their target price for the company from $148.00 to $170.00 in a research report on Monday, April 15th. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $137.43.

Masimo Trading Up 0.7 %

Shares of MASI stock opened at $136.14 on Monday. The stock has a market capitalization of $7.20 billion, a P/E ratio of 90.16 and a beta of 0.97. Masimo Co. has a fifty-two week low of $75.22 and a fifty-two week high of $190.82. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.22 and a current ratio of 2.18. The company has a 50 day moving average price of $135.77 and a 200 day moving average price of $116.78.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.82 by $0.43. The business had revenue of $548.90 million for the quarter, compared to analyst estimates of $545.69 million. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The company’s revenue was down 11.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.32 earnings per share. Equities research analysts predict that Masimo Co. will post 3.51 EPS for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.